Stock Groups

Corteva sees 2022 sales above market expectations -Breaking

[ad_1]

© Reuters. On June 3, 2019, the logo of Corteva Agriscience (a former DowDuPont division) is shown on a display at New York Stock Exchange. REUTERS/Brendan McDermid

(Reuters) – Corteva (NYSE:) Inc forecasts 2022 sales exceeding market expectations on Wednesday as insecticide- and seed manufacturer benefited from stronger demand and higher prices.

After a merger between Dow Chemical and Dupont in 2019, the company was spun off. It expects net sales to reach $16.7 billion to $17billion by 2022. This is higher than estimates of $16.62billion.

U.S. farmers have begun pre-buying chemicals and seeds to ensure supplies next spring. This is despite rising costs due to increased demand and tighter global supply.

Corteva projected operating earnings before interest tax depreciation, amortization, and amortization (EBITDA), of $2.8 billion to $2 billion. According to Refinitiv, IBES, analysts expected core earnings to reach $2.98 trillion.

Operating earnings before interest taxes, depreciation, amortization and amortization (OEM) for the fourth quarter were reported at $262 millions, 8 cents each share. They compare with 236 million, 4 cents each share a year prior.

In the fourth quarter, net sales of Wilmington, Delaware-based Company rose 8.48% and reached $3.48 million.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]